CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2017 International Liver Congress
Oncology Conference Multimedia
View more videos >>
Dr. Bruix Discusses the Application of Regorafenib in HCC
Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC
Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC
Oncology Conference Articles
Regorafenib Success Revives Hope in HCC
Jordi Bruix, MD, discusses the success of regorafenib in hepatocellular carcinoma and its impact on the field going forward.
Mipsagargin Demonstrates Clinical Benefit in Patients With Advanced HCC
The first-in-class prodrug, mipsagargin (G-202), showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.
SIRT Better-Tolerated Than Sorafenib in Advanced HCC
Liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated in patients with hepatocellular carcinoma, but the therapy did not improve rates of overall or progression-free survival over sorafenib.
Potential Biomarker for Survival Emerges in Hepatocellular Carcinoma
alpha fetoprotein level in the blood directly corresponded to the months of posttreatment survival in patients with hepatocellular carcinoma, independent of the type of treatment, regional differences, and disease etiology.
Nivolumab Provides Durable Responses in Sorafenib-Experienced HCC Patients
Sorafenib-experienced patients with advanced hepatocellular carcinoma had long-term responses to nivolumab of more than 1 year, according to findings from the CheckMate-040 trial.
DAA Therapy for Hepatitis C May Increase HCC Recurrence Risk
Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.
Combinations in HCC Gaining Traction
Nadine Abi-Jaoudeh, MD, discusses a study of tirapazamine and transarterial embolization and the promise of combinations in hepatocellular carcinoma.
MicroRNA-34a as a Therapeutic Target in HCC
MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma.
Independent Prognostic Markers of HCC Recurrence Identified
Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.
HCC Risk Comparable in Hepatitis C Patients Treated With DAA or Interferon
A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.